Response rate (≥PR) to therapy based on disease characteristics
| . | Arm B (4 mg) . | Arm C (5.5 mg) . | Arm B (4 mg) . | Arm C (5.5 mg) . |
|---|---|---|---|---|
| . | Prior bortezomib . | No prior bortezomib . | ||
| Response rate | 1/9 (11%) | 6/12 (50%) | 10/26 (38%) | 13/23 (57%) |
| sCR | 0 | 0 | 0 | 1 |
| CR | 0 | 0 | 1 | 0 |
| VGPR | 1 | 4 | 6 | 6 |
| PR | 0 | 2 | 3 | 6 |
| MR | 0 | 0 | 5 | 1 |
| . | Arm B (4 mg) . | Arm C (5.5 mg) . | Arm B (4 mg) . | Arm C (5.5 mg) . |
|---|---|---|---|---|
| . | Prior bortezomib . | No prior bortezomib . | ||
| Response rate | 1/9 (11%) | 6/12 (50%) | 10/26 (38%) | 13/23 (57%) |
| sCR | 0 | 0 | 0 | 1 |
| CR | 0 | 0 | 1 | 0 |
| VGPR | 1 | 4 | 6 | 6 |
| PR | 0 | 2 | 3 | 6 |
| MR | 0 | 0 | 5 | 1 |
| . | Intermediate or high risk . | Standard risk . | ||
|---|---|---|---|---|
| Response rate | 1/5 (20%) | 3/5 (60%) | 10/30 (33%) | 16/30 (53%) |
| sCR | 0 | 0 | 0 | 1 |
| CR | 0 | 0 | 1 | 0 |
| VGPR | 1 | 1 | 6 | 9 |
| PR | 0 | 2 | 3 | 6 |
| MR | 1 | 0 | 4 | 1 |
| . | Intermediate or high risk . | Standard risk . | ||
|---|---|---|---|---|
| Response rate | 1/5 (20%) | 3/5 (60%) | 10/30 (33%) | 16/30 (53%) |
| sCR | 0 | 0 | 0 | 1 |
| CR | 0 | 0 | 1 | 0 |
| VGPR | 1 | 1 | 6 | 9 |
| PR | 0 | 2 | 3 | 6 |
| MR | 1 | 0 | 4 | 1 |
| . | Refractory to lenalidomide . | Not refractory to lenalidomide . | ||
|---|---|---|---|---|
| Response rate | 5/16 (31%) | 8/16 (50%) | 6/19 (32%) | 11/19 (58%) |
| sCR | 0 | 1 | 0 | 0 |
| CR | 1 | 0 | 0 | 0 |
| VGPR | 2 | 4 | 5 | 6 |
| PR | 2 | 3 | 1 | 5 |
| MR | 3 | 1 | 2 | 0 |
| . | Refractory to lenalidomide . | Not refractory to lenalidomide . | ||
|---|---|---|---|---|
| Response rate | 5/16 (31%) | 8/16 (50%) | 6/19 (32%) | 11/19 (58%) |
| sCR | 0 | 1 | 0 | 0 |
| CR | 1 | 0 | 0 | 0 |
| VGPR | 2 | 4 | 5 | 6 |
| PR | 2 | 3 | 1 | 5 |
| MR | 3 | 1 | 2 | 0 |